| Identification | Back Directory | [Name]
4-[5-(4-Butylcyclohexyl)-1,2,4-oxadiazol-3-yl]-pyridinehydrochloride | [CAS]
388575-52-8 | [Synonyms]
PSN375963
PSN 375963 hydrochloride
5-(4-butylcyclohexyl)-3-pyridin-4-yl-1,2,4-oxadiazole
4-[5-(4-butylcyclohexyl)-1,2,4-oxadiazol-3-yl]-pyridine
4-[5-(4-Butylcyclohexyl)-1,2,4-oxadiazol-3-yl]-pyridinehydrochloride | [Molecular Formula]
C17H23N3O | [MDL Number]
MFCD01829706 | [MOL File]
388575-52-8.mol | [Molecular Weight]
285.38 |
| Chemical Properties | Back Directory | [Boiling point ]
440.1±47.0 °C(Predicted) | [density ]
1.060±0.06 g/cm3(Predicted) | [storage temp. ]
-20°C | [solubility ]
DMSO: >10mg/mL | [form ]
powder | [pka]
0.82±0.10(Predicted) | [color ]
white to off-white |
| Hazard Information | Back Directory | [Biochem/physiol Actions]
PSN-375963 is a GPR119 partial agonist. GPR119 is an orphan GPCR, expressed predominantly in pancreas and GI tract, that has been characterized. Its endogenous ligands are oleoylethanolamide (OEA) and oleoyl-lysophosphatidylcholine, lipid signaling molecules that regulate food intake and body weight. OEA decreases food intake, so GPR119 agonists are potential therapies for obesity. Initial studies showed that PSN-375963 has similar potency and partial efficacy compared to OEA. Further studies revealed that although OEA and PSN-375963 are GPR119 agonists, they have divergent effects on insulin secretion, calcium signaling, and cAMP production. | [storage]
Desiccate at RT |
|
| Company Name: |
|
| Tel: |
821-50328103-801 18930552037 |
| Website: |
https://www.chemicalbook.com/ShowSupplierProductsList13285/0.htm |
| Company Name: |
Sigma-Aldrich
|
| Tel: |
021-61415566 800-8193336 |
| Website: |
https://www.sigmaaldrich.cn |
| Company Name: |
BOC Sciences
|
| Tel: |
|
| Website: |
https://www.bocsci.com |
|